Rakuten Medical
June 22, 2026
Theater 2
Type: Company Presentation
Focus Area:
Oncology
Rakuten Medical is a clinical and commercial-stage biotech company advancing its investigational Alluminox™ platform, which is based on photoimmunotherapy. The company is developing the platform consisting of drug and device to treat cancers. Its lead asset, ASP-1929, an antibody-dye conjugate targeting EGFR, is currently in a global Phase 3 trial in combination with anti-PD-1 therapy. ASP-1929 has already received marketing approval in Japan since 2021 for unresectable, locally advanced, or recurrent head and neck cancer. As of today, the company has completed over 1,200 commercial treatments in Japan.
Company HQ City:
San Diego
Company HQ State:
CA
Company HQ Country:
United States
Year Founded:
2010
Lead Product in Development:
ASP-1929
CEO
Mickey Mikitani, CEO
Minami Maeda, President
Abhijit Bhatia, COO
Development Phase of Lead Product
Phase III
Number of Unlicensed Products Looking for Licensing
3
When you expect your next catalyst update?
May 2026
What is your next catalyst (value inflection) update?
First interim analysis of global phase 3 trial for ASP-1929 + anti-PD1 in first line head and neck cancer
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}